Dr Robert L. Coleman, US Oncology Research, reacts to how the case of a woman with advanced endometrial cancer was managed from diagnosis through treatment.
A 64-Year-Old Woman With Advanced Endometrial Carcinoma
A discussion on risk factors associated with endometrial cancer and the role of molecular testing to help evaluate for mismatch repair abnormality.
The rationale for using systemic therapy to treat patients with advanced endometrial cancer.
Variables that impact choice of therapy for patients with advanced endometrial cancer.
Recommendations on how to best prepare patients for chemotherapy, lenvatinib plus pembrolizumab, and other therapies used to treat advanced endometrial cancer.
What patients can expect in terms of prognosis when receiving systemic therapy for advanced endometrial cancer.
Future opportunities being explored in clinical trials that show promise in treating advanced endometrial cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
